united therapeutics glp-1 receptor agonist products agonists and next-generation metabolic hormone therapies in chronic kidney disease GLP-ONE + Receptor Activator
Description
Novo-Nordisk A/S, Eli Lilly And Company, Sanofi, AstraZeneca, Pfizer Inc., Amgen, Inc., and Innovent Biologics, Inc
A new blockbuster class of therapeutics, glucagon-like peptide 1 (GLP-1) analogs (eg, semaglutide), shows promise at curbing both diseases
GLP-1 therapies reduce inflammation across organs through rapid, weight-independent immune and metabolic effects.
Nearly 90% of Americans are now aware of GLP-1 drugs and their uses.
Results The study involved 2,835,398 patients with both NAFLD and type 2 diabetes
